Say hello to our team.
Chief Executive Officer
William Lee is an entrepreneur with over 10 years of experience in both the biotechnology and entertainment sectors. He is currently a shareholder and senior executive of EpiGentek Group Inc., a biotechnology reagents company specializing in epigenetics, and had also previously founded music licensing and gaming ventures. He has significant experience in management, operations, web development, and both B2B and B2C marketing. Having a passion for disruptive technologies, he invested in Bitcoin in 2013 and subsequently Ethereum in its early days. William Lee studied at New York University and Carnegie Mellon University. While pursuing his MBA at the Carnegie Mellon Tepper School of Business, William realized the vast startup opportunity in the blockchain space and sought to bring the disruptive technology into consumer biotech.
Adam Weiwei Li, MD, Ph.D.
Chief Scientific Officer
Dr. Adam Li is the scientific founder and CSO of EpiGentek Group, Inc. with more than 20 years of experience in oncology and pharmacology as well as 15 years of experience in epigenetic research. His publication list includes 46 peer-reviewed papers in the cancer and epigenetic fields. As the first inventor, he has filed 11 patent applications related to epigenetic test methods and medical cosmetics, in which 4 patents were issued. Dr. Li completed his postdoctoral training at Memorial Sloan-Kettering Cancer Center and served as faculty-level attending biologist at Memorial Hospital in New York prior to joining EpiGentek. He was also the visiting professor at University of South China Medical College and a reviewer of several top biological journals including Cancer Research and Nucleic Acid Research.
Chief Financial Officer
Jessica has more than 20 years of experience in accounting, finance, banking, and business management. She is a co-founder and the CFO of EpiGentek Group, Inc. where she developed and facilitated financial strategies, budget and cost management, and accounting operations to ultimately increase overall enterprise value. Before joining EpiGentek, she worked at several CPA firms as well as in the banking sector in New York. She holds a bachelor’s degree in finance and an MBA from the New York Institute of Technology School of Management with a concentration in accounting.
Business Strategy Lead
Ashley Pottash is a strategic and creative brand builder with more than 8 years’ experience in the fashion and beauty industries. She specializes in visual merchandising for luxury brands and is Senior Manager of Global Visual Merchandising at Coty, inc. for Marc Jacobs and Calvin Klein fragrances. Ashley served as Manager of Merchandise Development and Purchasing at CHANEL for all makeup, skincare, and fragrance point of sale collateral. After leaving CHANEL, she spearheaded visual merchandising and store design for the innovative beauty and skincare brand, Charlotte Tilbury. Ashley graduated early from the Robins School of Business at the University of Richmond with a focus on business and marketing.
Software Development Lead
Stephen Fiser is a software engineer specializing in blockchain technology. After graduating from the University of Arkansas with a degree in biophysics, Stephen worked in the corporate information technology sector. Wanting to focus on emerging technologies, he moved to New York City and shifted gears to work with startup companies until 2014 when he founded Blue Bear Digital Inc., a full-fledged software development agency.
Richard Wildnauer, Ph.D.
Former CEO of NeoStrata. Held senior positions at Johnson & Johnson. Served as R&D director and board chairman at various organizations. Currently serves as Board Director at Dynamis Skin Sciences. Holds Ph.D. and MBA degrees. Numerous dermatology publications and various membership associations.
James Wang, MD
Board certified dermatologist and dermatopathologist with clinical practices. CEO of Curebiotech, Inc. with focus on immune and stem cell therapies for skin disorders. Harvard MD and MBA. Trained at UCLA, Memorial Sloan Kettering Cancer Center, and NY-Presbyterian Hospital.
Co-founder and COO of QBRICS, Inc. Founder of Blockchain Healthcare Review. Experienced health information technology blockchain implementation strategist. MS in Biomedical Informatics. Enterprise strategy consultant in pharma. Currently advises several companies in the blockchain space.
Rebecca Fry, Ph.D.
Distinguished professor and associate chair at UNC-Chapel Hill. Principal investigator of multi-million dollar NIH-funded grants. Ph.D. in biology. Researches epigenetic mechanisms that relate toxic substances to children’s health. Served on various scientific committees including the FDA.
Founding partner of Thompson Bukher LLP. Specializes in investment funds, technology startups, securities, venture capital, and corporate matters. Advises multiple organizations in the blockchain space. Served as US legal counsel in SingularityNET crowdsale.